The expression of sirtuins in breast cancer and their prognostic and clinicopathological significance: a systematic review
-
Ehsan Naseri
,
Zohreh Abdolvahabi
,
Banafsheh Safizadeh
,
Hannaneh Zarrinnahad
,
Yousef Moradi
,
Marzieh Soheili
,
Hamid Reza Baradaran
,
Mitra Nourbakhsh
Abstract
Objectives: Sirtuins (SIRTs) are a highly conserved family of enzymes that play an important role in cancer emergence and progression including breast cancer. In this review, changes in the expression of different SIRTs in breast cancer and their association with metastasis and cancer grade were investigated.
Methods: This study was performed on 44 selected articles on breast cancer which were extracted from PubMed, Scopus, and Web of Science. Among the selected articles, there were 31 case-control and 13 cohort studies with a total of 7326 and 4760 participants, respectively.
Results: In most studies SIRT1, SIRT5, and SIRT7 expression levels were higher than the controls, while the expression levels of SIRT4 and SIRT6 were lower. Elevated levels of SIRT1 was associated with increased risk of distant metastatic relapse (DMR), death, and recurrence, as well as reduced relapse-free survival (RFS). Also, there was a significant correlation between increased levels of SIRT1 and metastasis of lymph nodes and other tissues. Reduced levels of SIRT4 were associated with decreased overall survival (OS).
Conclusion: Our findings suggest that the elevated levels of SIRT1, SIRT5, and SIRT7 may have the potential value for use in the diagnosis of breast cancer. Increased levels of SIRT1 can be used as a prognostic marker.
References:
1. Imai S-I, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795.
2. Kozako T, Suzuki T, Yoshimitsu M, Arima N, Honda S-i, Soeda S. Anticancer agents targeted to sirtuins. Molecules. 2014;19(12):20295-313.
3. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. BioMed Research International. 2011;2011.
4. Rajabi N, Galleano I, Madsen AS, Olsen CA. Targeting sirtuins: Substrate specificity and inhibitor design. Progress in molecular biology and translational science. 154: Elsevier; 2018. p. 25-69.
5. Voelter-Mahlknecht S, Mahlknecht U. The sirtuins in the pathogenesis of cancer. Clinical epigenetics. 2010;1(3):71.
6. Zhu S, Dong Z, Ke X, Hou J, Zhao E, Zhang K, et al., editors. The roles of sirtuins family in cell metabolism during tumor development. Seminars in cancer biology; 2019: Elsevier.
7. Zhao E, Hou J, Ke X, Abbas MN, Kausar S, Zhang L, et al. The Roles of Sirtuin Family Proteins in Cancer Progression. Cancers. 2019;11(12):1949.
8. Jing H, Hu J, He B, Abril YLN, Stupinski J, Weiser K, et al. A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer cell. 2016;29(3):297-310.
9. Huang K-H, Hsu C-C, Fang W-L, Chi C-W, Sung M-T, Kao H-L, et al. SIRT3 expression as a biomarker for better prognosis in gastric cancer. World journal of surgery. 2014;38(4):910-7.
10. Xiong Y, Wang M, Zhao J, Han Y, Jia L. Sirtuin 3: A Janus face in cancer. International journal of oncology. 2016;49(6):2227-35.
11. Ozden O, Park S-H, Wagner BA, Song HY, Zhu Y, Vassilopoulos A, et al. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radical Biology and Medicine. 2014;76:163-72.
12. Xia X, Xiao C, Shan H. Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway. Eur Rev Med Pharmacol Sci. 2017;21(6):1248-53.
13. Liou CJ, Wei CH, Chen YL, Cheng CY, Wang CL, Huang WC. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid beta-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;49(5):1870-84.
14. Bringman-Rodenbarger LR, Guo AH, Lyssiotis CA, Lombard DB. Emerging roles for SIRT5 in metabolism and cancer. Antioxidants & redox signaling. 2018;28(8):677-90.
15. Bai L, Lin G, Sun L, Liu Y, Huang X, Cao C, et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. Oncotarget. 2016;7(26):40377.
16. Lerrer B, Gertler AA, Cohen HY. The complex role of SIRT6 in carcinogenesis. Carcinogenesis. 2016;37(2):108-18.
17. Malik S, Villanova L, Tanaka S, Aonuma M, Roy N, Berber E, et al. SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Scientific reports. 2015;5(1):1-9.
18. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. The Journal of biological chemistry. 2011;286(29):25992-6002.
19. Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, et al. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Molecular endocrinology (Baltimore, Md). 2013;27(3):480-90.
20. Sung JY, Kim R, Kim JE, Lee J. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer science. 2010;101(7):1738-44.
21. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006;95(8):1056-61.
22. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity. Journal of Cancer. 2018;9(11):2012-23.
23. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Human pathology. 2011;42(2):204-13.
24. Rizk SM, Shahin NN, Shaker OG. Association between SIRT1 Gene Polymorphisms and Breast Cancer in Egyptians. PLoS One. 2016;11(3):e0151901.
25. Hamdy S, Omnia M, Salah A-R, Mohamed S, Amani K. Relative Transcription Expression Level of SIRT1, SIRT2 and SIRT3 in Correlation to the Expression of a Set of Selected Cancer Related Genes in Human Breast Cancer. OnLine Journal of Biological Sciences. 2018;18(2).
26. Yao Y, Liu T, Wang X, Zhang D. The Contrary Effects of Sirt1 on MCF7 Cells Depend on CD36 Expression Level. The Journal of surgical research. 2019;238:248-54.
27. Xu Y, Qin Q, Chen R, Wei C, Mo Q. SIRT1 promotes proliferation, migration, and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1 (POLD1). Biochemical and biophysical research communications. 2018;502(3):351-7.
28. Zou Q, Tang Q, Pan Y, Wang X, Dong X, Liang Z, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Experimental and therapeutic medicine. 2017;14(2):1009-16.
29. Abdelmawgoud H, El Awady RR. Effect of Sirtuin 1 inhibition on matrix metalloproteinase 2 and Forkhead box O3a expression in breast cancer cells. Genes & diseases. 2017;4(4):240-6.
30. Kuo SJ, Lin HY, Chien SY, Chen DR. SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein. Oncol Rep. 2013;30(1):125-30.
31. Jia Y, Zhao J, Yang J, Shao J, Cai Z. miR-301 regulates the SIRT1/SOX2 pathway via CPEB1 in the breast cancer progression. Molecular therapy oncolytics. 2021;22:13-26.
32. Yue Y, He L, Tian M, Li X. Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells. Cellular and molecular biology (Noisy-le-Grand, France). 2020;66(3):204-10.
33. Zhang W, Luo J, Yang F, Wang Y, Yin Y, Strom A, et al. BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1. Sci Rep. 2016;6:22034.
34. Igci M, Kalender ME, Borazan E, Bozgeyik I, Bayraktar R, Bozgeyik E, et al. High-throughput screening of Sirtuin family of genes in breast cancer. Gene. 2016;586(1):123-8.
35. McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, et al. SIRT2: tumour suppressor or tumour promoter in operable breast cancer? European journal of cancer (Oxford, England : 1990). 2014;50(2):290-301.
36. Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, et al. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC cancer. 2014;14:604.
37. Kim H, Lee KH, Park IA, Chung YR, Im SA, Noh DY, et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv : an international journal of pathology. 2015;467(5):563-70.
38. Cao YW, Li WQ, Wan GX, Li YX, Du XM, Li YC, et al. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer. Journal of experimental & clinical cancer research : CR. 2014;33:97.
39. Chung SY, Jung YY, Park IA, Kim H, Chung YR, Kim JY, et al. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clinical & experimental metastasis. 2016;33(2):179-85.
40. Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer research. 2011;31(12):4115-25.
41. Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH, Ahn SD, et al. Expression of FOXM1 and related proteins in breast cancer molecular subtypes. International journal of experimental pathology. 2016;97(2):170-7.
42. Tan J, Liu Y, Maimaiti Y, Wang C, Yan Y, Zhou J, et al. Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer. OncoTargets and therapy. 2018;11:2051-61.
43. Swelim H, Mansour O, Abdel-Rahman S, Shwaireb M, Kazem A. Relative Transcription Expression Level of SIRT1, SIRT2 and SIRT3 in Correlation to the Expression of a Set of Selected Cancer Related Genes in Human Breast Cancer. OnLine Journal of Biological Sciences. 2018;18(2).
44. Kim HS, Moon S, Paik JH, Shin DW, Kim LS, Park CS, et al. Activation of the 5'-AMP-Activated Protein Kinase in the Cerebral Cortex of Young Senescence-Accelerated P8 Mice and Association with GSK3beta- and PP2A-Dependent Inhibition of p-tau(3)(9)(6) Expression. Journal of Alzheimer's disease : JAD. 2015;46(1):249-59.
45. Shan W, Jiang Y, Yu H, Huang Q, Liu L, Guo X, et al. HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. American journal of cancer research. 2017;7(5):1213-26.
46. Shi P, Zhou M, Yang Y. Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients. Irish Journal of Medical Science (1971-). 2020;189:83-9.
47. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne A, George W, et al. Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006;95(8):1056-61.
48. Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Human pathology. 2014;45(5):1071-7.
49. McGlynn LM, McCluney S, Jamieson NB, Thomson J, MacDonald AI, Oien K, et al. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. PLoS One. 2015;10(6):e0131344.
50. Kim H-S, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer cell. 2010;17(1):41-52.
51. Poorhosseini SM, Hashemi M, Alipour Olyaei N, Izadi A, Moslemi E, Ravesh Z, et al. New gene profiling in determination of breast cancer recurrence and prognosis in Iranian women. Asian Pacific Journal of Cancer Prevention. 2016;17(S3):155-60.
52. Shi Q, Liu T, Zhang X, Geng J, He X, Nu M, et al. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncology letters. 2016;12(4):2606-12.
53. Wang L, Zhou H, Wang Y, Cui G, Di L. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4. Cell death & disease. 2015;6(1):e1620-e.
54. Huang G, Lin Y, Zhu G. SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells. International journal of clinical and experimental pathology. 2017;10(12):11849-56.
55. He S, Jia Q, Zhou L, Wang Z, Li M. SIRT5 is involved in the proliferation and metastasis of breast cancer by promoting aerobic glycolysis. Pathology, research and practice. 2022;235:153943.
56. Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, et al. The RUNX2 transcription factor negatively regulates SIRT6 expression to alter glucose metabolism in breast cancer cells. Journal of cellular biochemistry. 2015;116(10):2210-26.
57. Wang D, Li C, Zhang X. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. DNA and cell biology. 2014;33(9):581-90.
58. Hong OY, Jang HY, Lee YR, Jung SH, Youn HJ, Kim JS. Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells. Sci Rep. 2022;12(1):12125.
59. Aljada A, Saleh AM, Alkathiri M, Shamsa HB, Al-Bawab A, Nasr A. Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer. Breast cancer : basic and clinical research. 2015;9:3-8.
60. Geng Q, Peng H, Chen F, Luo R, Li R. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. International journal of clinical and experimental pathology. 2015;8(2):1938-45.
61. Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Medical oncology (Northwood, London, England). 2012;29(5):3240-9.
62. Chung YR, Kim H, Park SY, Park IA, Jang JJ, Choe JY, et al. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Human pathology. 2015;46(7):1027-35.
63. Jin MS, Hyun CL, Park IA, Kim JY, Chung YR, Im SA, et al. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(4):4743-53.
64. He S, He C, Yuan H, Xiong S, Xiao Z, Chen L. The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cellular Physiology and Biochemistry. 2014;34(6):2061-9.
65. Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013;34(7):1476-86.
66. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity. Journal of Cancer. 2018;9(11):2012.
67. Huang G, Lin Y, Zhu G. SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells. International journal of clinical and experimental pathology. 2017;10(12):11849.
68. Shi Q, Liu T, Zhang X, Geng J, He X, Nu M, et al. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncology letters. 2016;12(4):2606-12.
69. Geng Q, Peng H, Chen F, Luo R, Li R. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. International journal of clinical and experimental pathology. 2015;8(2):1938.
70. Abdolvahabi Z, Nourbakhsh M, Hosseinkhani S, Hesari Z, Alipour M, Jafarzadeh M, et al. MicroRNA‐590‐3P suppresses cell survival and triggers breast cancer cell apoptosis via targeting sirtuin‐1 and deacetylation of p53. Journal of cellular biochemistry. 2019;120(6):9356-68.
71. Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, et al. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer research. 2018;78(2):372-86.
72. Chang L, Xi L, Liu Y, Liu R, Wu Z, Jian Z. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1. Molecular medicine reports. 2018;17(1):342-9.
73. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes & development. 2006;20(9):1075-80.
74. Huang G, Cheng J, Yu F, Liu X, Yuan C, Liu C, et al. Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer. Oncology reports. 2016;35(5):2801-10.
75. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer cell. 2013;23(4):450-63.
76. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452(7186):492-6.
1. Imai S-I, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795.
2. Kozako T, Suzuki T, Yoshimitsu M, Arima N, Honda S-i, Soeda S. Anticancer agents targeted to sirtuins. Molecules. 2014;19(12):20295-313.
3. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. BioMed Research International. 2011;2011.
4. Rajabi N, Galleano I, Madsen AS, Olsen CA. Targeting sirtuins: Substrate specificity and inhibitor design. Progress in molecular biology and translational science. 154: Elsevier; 2018. p. 25-69.
5. Voelter-Mahlknecht S, Mahlknecht U. The sirtuins in the pathogenesis of cancer. Clinical epigenetics. 2010;1(3):71.
6. Zhu S, Dong Z, Ke X, Hou J, Zhao E, Zhang K, et al., editors. The roles of sirtuins family in cell metabolism during tumor development. Seminars in cancer biology; 2019: Elsevier.
7. Zhao E, Hou J, Ke X, Abbas MN, Kausar S, Zhang L, et al. The Roles of Sirtuin Family Proteins in Cancer Progression. Cancers. 2019;11(12):1949.
8. Jing H, Hu J, He B, Abril YLN, Stupinski J, Weiser K, et al. A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer cell. 2016;29(3):297-310.
9. Huang K-H, Hsu C-C, Fang W-L, Chi C-W, Sung M-T, Kao H-L, et al. SIRT3 expression as a biomarker for better prognosis in gastric cancer. World journal of surgery. 2014;38(4):910-7.
10. Xiong Y, Wang M, Zhao J, Han Y, Jia L. Sirtuin 3: A Janus face in cancer. International journal of oncology. 2016;49(6):2227-35.
11. Ozden O, Park S-H, Wagner BA, Song HY, Zhu Y, Vassilopoulos A, et al. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radical Biology and Medicine. 2014;76:163-72.
12. Xia X, Xiao C, Shan H. Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway. Eur Rev Med Pharmacol Sci. 2017;21(6):1248-53.
13. Liou CJ, Wei CH, Chen YL, Cheng CY, Wang CL, Huang WC. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid beta-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;49(5):1870-84.
14. Bringman-Rodenbarger LR, Guo AH, Lyssiotis CA, Lombard DB. Emerging roles for SIRT5 in metabolism and cancer. Antioxidants & redox signaling. 2018;28(8):677-90.
15. Bai L, Lin G, Sun L, Liu Y, Huang X, Cao C, et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. Oncotarget. 2016;7(26):40377.
16. Lerrer B, Gertler AA, Cohen HY. The complex role of SIRT6 in carcinogenesis. Carcinogenesis. 2016;37(2):108-18.
17. Malik S, Villanova L, Tanaka S, Aonuma M, Roy N, Berber E, et al. SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Scientific reports. 2015;5(1):1-9.
18. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. The Journal of biological chemistry. 2011;286(29):25992-6002.
19. Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, et al. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Molecular endocrinology (Baltimore, Md). 2013;27(3):480-90.
20. Sung JY, Kim R, Kim JE, Lee J. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer science. 2010;101(7):1738-44.
21. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006;95(8):1056-61.
22. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity. Journal of Cancer. 2018;9(11):2012-23.
23. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Human pathology. 2011;42(2):204-13.
24. Rizk SM, Shahin NN, Shaker OG. Association between SIRT1 Gene Polymorphisms and Breast Cancer in Egyptians. PLoS One. 2016;11(3):e0151901.
25. Hamdy S, Omnia M, Salah A-R, Mohamed S, Amani K. Relative Transcription Expression Level of SIRT1, SIRT2 and SIRT3 in Correlation to the Expression of a Set of Selected Cancer Related Genes in Human Breast Cancer. OnLine Journal of Biological Sciences. 2018;18(2).
26. Yao Y, Liu T, Wang X, Zhang D. The Contrary Effects of Sirt1 on MCF7 Cells Depend on CD36 Expression Level. The Journal of surgical research. 2019;238:248-54.
27. Xu Y, Qin Q, Chen R, Wei C, Mo Q. SIRT1 promotes proliferation, migration, and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1 (POLD1). Biochemical and biophysical research communications. 2018;502(3):351-7.
28. Zou Q, Tang Q, Pan Y, Wang X, Dong X, Liang Z, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Experimental and therapeutic medicine. 2017;14(2):1009-16.
29. Abdelmawgoud H, El Awady RR. Effect of Sirtuin 1 inhibition on matrix metalloproteinase 2 and Forkhead box O3a expression in breast cancer cells. Genes & diseases. 2017;4(4):240-6.
30. Kuo SJ, Lin HY, Chien SY, Chen DR. SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein. Oncol Rep. 2013;30(1):125-30.
31. Jia Y, Zhao J, Yang J, Shao J, Cai Z. miR-301 regulates the SIRT1/SOX2 pathway via CPEB1 in the breast cancer progression. Molecular therapy oncolytics. 2021;22:13-26.
32. Yue Y, He L, Tian M, Li X. Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells. Cellular and molecular biology (Noisy-le-Grand, France). 2020;66(3):204-10.
33. Zhang W, Luo J, Yang F, Wang Y, Yin Y, Strom A, et al. BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1. Sci Rep. 2016;6:22034.
34. Igci M, Kalender ME, Borazan E, Bozgeyik I, Bayraktar R, Bozgeyik E, et al. High-throughput screening of Sirtuin family of genes in breast cancer. Gene. 2016;586(1):123-8.
35. McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, et al. SIRT2: tumour suppressor or tumour promoter in operable breast cancer? European journal of cancer (Oxford, England : 1990). 2014;50(2):290-301.
36. Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, et al. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC cancer. 2014;14:604.
37. Kim H, Lee KH, Park IA, Chung YR, Im SA, Noh DY, et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv : an international journal of pathology. 2015;467(5):563-70.
38. Cao YW, Li WQ, Wan GX, Li YX, Du XM, Li YC, et al. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer. Journal of experimental & clinical cancer research : CR. 2014;33:97.
39. Chung SY, Jung YY, Park IA, Kim H, Chung YR, Kim JY, et al. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clinical & experimental metastasis. 2016;33(2):179-85.
40. Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer research. 2011;31(12):4115-25.
41. Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH, Ahn SD, et al. Expression of FOXM1 and related proteins in breast cancer molecular subtypes. International journal of experimental pathology. 2016;97(2):170-7.
42. Tan J, Liu Y, Maimaiti Y, Wang C, Yan Y, Zhou J, et al. Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer. OncoTargets and therapy. 2018;11:2051-61.
43. Swelim H, Mansour O, Abdel-Rahman S, Shwaireb M, Kazem A. Relative Transcription Expression Level of SIRT1, SIRT2 and SIRT3 in Correlation to the Expression of a Set of Selected Cancer Related Genes in Human Breast Cancer. OnLine Journal of Biological Sciences. 2018;18(2).
44. Kim HS, Moon S, Paik JH, Shin DW, Kim LS, Park CS, et al. Activation of the 5'-AMP-Activated Protein Kinase in the Cerebral Cortex of Young Senescence-Accelerated P8 Mice and Association with GSK3beta- and PP2A-Dependent Inhibition of p-tau(3)(9)(6) Expression. Journal of Alzheimer's disease : JAD. 2015;46(1):249-59.
45. Shan W, Jiang Y, Yu H, Huang Q, Liu L, Guo X, et al. HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. American journal of cancer research. 2017;7(5):1213-26.
46. Shi P, Zhou M, Yang Y. Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients. Irish Journal of Medical Science (1971-). 2020;189:83-9.
47. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne A, George W, et al. Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006;95(8):1056-61.
48. Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Human pathology. 2014;45(5):1071-7.
49. McGlynn LM, McCluney S, Jamieson NB, Thomson J, MacDonald AI, Oien K, et al. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. PLoS One. 2015;10(6):e0131344.
50. Kim H-S, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer cell. 2010;17(1):41-52.
51. Poorhosseini SM, Hashemi M, Alipour Olyaei N, Izadi A, Moslemi E, Ravesh Z, et al. New gene profiling in determination of breast cancer recurrence and prognosis in Iranian women. Asian Pacific Journal of Cancer Prevention. 2016;17(S3):155-60.
52. Shi Q, Liu T, Zhang X, Geng J, He X, Nu M, et al. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncology letters. 2016;12(4):2606-12.
53. Wang L, Zhou H, Wang Y, Cui G, Di L. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4. Cell death & disease. 2015;6(1):e1620-e.
54. Huang G, Lin Y, Zhu G. SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells. International journal of clinical and experimental pathology. 2017;10(12):11849-56.
55. He S, Jia Q, Zhou L, Wang Z, Li M. SIRT5 is involved in the proliferation and metastasis of breast cancer by promoting aerobic glycolysis. Pathology, research and practice. 2022;235:153943.
56. Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, et al. The RUNX2 transcription factor negatively regulates SIRT6 expression to alter glucose metabolism in breast cancer cells. Journal of cellular biochemistry. 2015;116(10):2210-26.
57. Wang D, Li C, Zhang X. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. DNA and cell biology. 2014;33(9):581-90.
58. Hong OY, Jang HY, Lee YR, Jung SH, Youn HJ, Kim JS. Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells. Sci Rep. 2022;12(1):12125.
59. Aljada A, Saleh AM, Alkathiri M, Shamsa HB, Al-Bawab A, Nasr A. Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer. Breast cancer : basic and clinical research. 2015;9:3-8.
60. Geng Q, Peng H, Chen F, Luo R, Li R. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. International journal of clinical and experimental pathology. 2015;8(2):1938-45.
61. Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Medical oncology (Northwood, London, England). 2012;29(5):3240-9.
62. Chung YR, Kim H, Park SY, Park IA, Jang JJ, Choe JY, et al. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Human pathology. 2015;46(7):1027-35.
63. Jin MS, Hyun CL, Park IA, Kim JY, Chung YR, Im SA, et al. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(4):4743-53.
64. He S, He C, Yuan H, Xiong S, Xiao Z, Chen L. The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cellular Physiology and Biochemistry. 2014;34(6):2061-9.
65. Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013;34(7):1476-86.
66. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity. Journal of Cancer. 2018;9(11):2012.
67. Huang G, Lin Y, Zhu G. SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells. International journal of clinical and experimental pathology. 2017;10(12):11849.
68. Shi Q, Liu T, Zhang X, Geng J, He X, Nu M, et al. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncology letters. 2016;12(4):2606-12.
69. Geng Q, Peng H, Chen F, Luo R, Li R. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. International journal of clinical and experimental pathology. 2015;8(2):1938.
70. Abdolvahabi Z, Nourbakhsh M, Hosseinkhani S, Hesari Z, Alipour M, Jafarzadeh M, et al. MicroRNA‐590‐3P suppresses cell survival and triggers breast cancer cell apoptosis via targeting sirtuin‐1 and deacetylation of p53. Journal of cellular biochemistry. 2019;120(6):9356-68.
71. Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, et al. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer research. 2018;78(2):372-86.
72. Chang L, Xi L, Liu Y, Liu R, Wu Z, Jian Z. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1. Molecular medicine reports. 2018;17(1):342-9.
73. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes & development. 2006;20(9):1075-80.
74. Huang G, Cheng J, Yu F, Liu X, Yuan C, Liu C, et al. Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer. Oncology reports. 2016;35(5):2801-10.
75. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer cell. 2013;23(4):450-63.
76. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452(7186):492-6.
| Files | ||
| Issue | Vol 2 No 2 (2024): . | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/abi.v2i2.17932 | |
| Keywords | ||
| Sirtuins Breast Cancer SIRTs clinicopathological survival prognostic | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Naseri E, Abdolvahabi Z, Safizadeh B, Zarrinnahad H, Moradi Y, Soheili M, Baradaran HR, Nourbakhsh M. The expression of sirtuins in breast cancer and their prognostic and clinicopathological significance: a systematic review. ABI. 2024;2(2):68-77.
